Dr Rosanne Dunn, Co-Founder and Chief Scientific Officer at HaemaLogiX, explores how discovery of a new class of tumour‑specific antigens is transforming how we treat plasma cell dyscrasias. For more than two decades, progress in multiple myeloma has been marked by sustained advances in drug development that have not translated into true curability. Proteasome inhibitors, […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!